



**Table S1.** Nucleotide sequences used for Crip editing, digital PCR, and Sanger sequencing.

ssODN template containing the stop tag (in red)	TGCCACAAAAGATACTTTCCATAAGATCAAGCTGGATGTG <b>CGTAAC</b> <b>TAGCTGA</b> AGTTGATACACAAGAAATGCTGAGAACTTGGAAGTGATAT
ddPCR primers	FMR1taqF: GAACGTCTAAGATCTGTTAATCCCA FMR1taqR2: CCATTTTGGCCAAAGTCCACCA
LNA probes by IDT	FMR1wt-HEX: /5HEX/CCA +GAA +GA+C T+TA +CG/3IABkFQ Stoptag-FAM: /56-FAM/CGTAA+C+TA+G+C+T+GA/3IABkFQ
Primers for PCR/Sanger sequencing	PCR Forward: GAACGTCTAAGATCTGTTAATCCCA Reverse: CCATTTTGGCCAAAGTCCACCA Sequencing GAACGTCTAAGATCTGTTAATCCCA CCATTTTGGCCAAAGTCCACCA


**Table S2.** List of antibodies.

Cell type	Antibody	Catalog	Dilution
iPSC	Nanog	Abcam Ab21624	1:200
	TRA1-60	Stem Cell Technologies #60064	1:200
	OCT3/4	Santa Cruz SC-8628	1:500
	SSEA-4	Santa Cruz SC-21704	1:500
cNPC	Nestin	Abcam ab92391	1:500
	SOX1	R&D AF3369	1:100
	Foxg1	Abcam ab196868	1:500
	Ki67	BD 556003	1:200
Astrocytes	GFAP	Millipore AB5804	1:250
Cortical neurons	Tuj1	Millipore MAB5564	1:200
	Tuj1	Covance	1:1000
	Map2	Encor Biotechnology AB_2138173	1:1000
	VGLUT1	Synaptic System 135304	1:200
	GABA	Sigma a2052	1:200


**Table S3.** List of TaqMan probes and primer sets (Applied Biosystems).

Gene	reference
<i>OCT3/4</i>	Hs04260367_gH
<i>Nanog</i>	Hs02387400_g1
<i>FMR1</i>	Hs00924547_m1
<i>PAX6</i>	Hs01088114_m1
<i>SOX1</i>	Hs01057642_s1
<i>Nestin</i>	Hs04187831_g1
<i>MAP2</i>	Hs00258900_m1
<i>S100B</i>	Hs00902901_m1
<i>FOXG1</i>	Hs01850784_s1
<i>SIX3</i>	Hs00193667_m1
<i>MAP1B</i>	Hs01067016_m1
<i>GRIA2</i>	Hs00181331_m1
<i>GABRA2</i>	Hs00168069_m1
<i>SNAP25</i>	Hs00938957_m1
<i>SYN1</i>	Hs00199577_m1
<i>PSD95</i>	Hs01555373_m1
<i>TUBB3</i>	Hs00964962_g1
<i>GFAP</i>	Hs00909233_m1


<i>VIM</i>	Hs00958111_m1
<i>SYP</i>	Hs00300531_m1
<i>SLC17A7</i>	Hs00220404_m1
<i>NTRK2</i>	Hs00178811_m1
<i>GRIN2B</i>	Hs01002012_m1
<i>ACTB</i>	Hs01060665_g1
<i>GAPDH</i>	Hs02786624_g1




**Figure S1. Genomic stability testing of the *FMR1* KO iPSC line.** qPCR-based chromosomal abnormality analysis in the eight common critical areas within chr1q, chr8q, chr10p, chr12p, chr17q, chr18q, chr20q, and chrXp showed amplification in chr20q only.




**Figure S2. Common transcriptional deregulations between *FMR1*-KO NPCs and Neurons.** A) Venn diagram of the differentially expressed genes in *FMR1* KO NPCs and *FMR1* KO neurons. B) Fold change distribution for the common set of genes differentially expressed in *FMR1* KO NPCs and Neurons. (C) GO terms defining the significant functional enrichment for the genes that are downregulated in *FMR1* KO NPCs and *FMR1* KO neurons. (D) GO terms defining the significant functional enrichment for the genes that are upregulated in *FMR1* KO NPCs and *FMR1* KO neurons. (E) Overlap between the genes significantly downregulated in *FMR1* KO NPCs and neurons, and the list of autism risk genes analyzed. (F) Overlap between the genes significantly upregulated in *FMR1* KO NPCs and neurons, and the list of autism risk genes. (G) Overlap between the genes significantly downregulated in *FMR1* KO NPCs and neurons, and the list of FMRP targets analyzed. (H) Overlap between the genes significantly upregulated in *FMR1* KO NPCs and neurons, and the list of FMRP targets analyzed.



**Figure S3. Validation of differential gene expression by Real-Time PCR.** Normalized expression levels of *FOXG1*, *SIX3*, and *TH* mRNA in *FMR1* KO NPCs and neurons compared to control cells.



**Figure S4.** Validation of differential gene expression by Real-Time PCR. MEA raster plots from MEA recordings showing. Changes in electrical activity in week 3 to week 4 in cortical neurons from (A) Isogenic control and *FMR1* KO, and (B) Control and FX11-7.



**Figure S5.** Differential NMDA response between control and FXS IPSC-derived NPCs and Neurons

## Supplementary results

### *Common deregulations between FMR1 KO NPCs and FMR1 KO neurons.*

The analysis of our RNA sequencing data shows that a similar number of genes were differentially expressed at the NPC and differentiating neuron stages (**Supplementary Figure 2**). Those genes include genes associated with synapse and neuronal formation, autism-associated genes, and FMRP targets. We then wondered how common the deregulated genes in *FMR1* KO cell lines at the NPC and neuronal stages are. Comparing the two gene lists (**Figure 6A** and **Figure 6B**), we found a set of 536 genes (40% of the DEGs) that were deregulated at both the NPC and neuronal stages (**Supplementary Figure 2**). We further examined the fold changes in the list of commonly deregulated genes. We found that 88% of them were either up or downregulated at both stages (**Supplementary Figure 2**). Genes that were found upregulated in *FMR1* KO NPCs and neurons are involved in brain development, neurogenesis, and forebrain specification (**Supplementary Figure 2**). These genes include *SIX3* and *FOXP1* which code for transcription factors whose mutations are respectively responsible for holoprosencephaly/schizencephaly [1], Rett-like, and *FOXP1* [2] syndromes. We have actually validated by Q-PCR the increased expression of *SIX3* and *FOXP1* in *FMR1* KO NPCs and Neurons ( $F_{SIX3} \text{ Genotype}=1145$ ;  $df=1$ ;  $p<0.0001$ ;  $t_{NPCs}=18.27$ ;  $p<0.001$ ;  $t_{Neurons}=29.60$ ;  $p<0.001$ ;  $F_{FOXP1} \text{ Genotype}=264.4$ ;  $df=1$ ;  $p<0.0001$ ;  $t_{NPCs}=7.491$ ;  $p<0.001$ ;  $t_{Neurons}=15.50$ ;  $p<0.001$ ). Genes downregulated in the *FMR1* KO NPCs and neurons were significantly enriched in synaptic function, axon, neuronal projections, and DNA binding transcription factor (**Supplementary Figure 2**). These functional enrichments observed from common deregulations in *FMR1* KO NPCs and neurons suggest that the regional specification of *FMR1* KO cells and their neuronal differentiation are impaired, leaving the cells in a progenitor-like state. We have also assessed these gene lists for enrichment in ASD-related genes and FMRP targets. Similarly, to what was observed in **Figure 6**, we found significant enrichment in ASD-related genes (39/262;  $p < 9.309e-05$ ) (**Supplementary Figure 2E**) and in FMRP targets (73/262;  $p < 2.526e-07$ ) (**Supplementary Figure 2G**) among the list of genes that are commonly downregulated in *FMR1* KO NPCs and neurons.

## References

1. Hehr, U.; Pineda-Alvarez, D. E.; Uyanik, G.; Hu, P.; Zhou, N.; Hehr, A.; Schell-Apacik, C.; Altus, C.; Daumer-Haas, C.; Meiner, A.; Steuernagel, P.; Roessler, E.; Winkler, J.; Muenke, M., Heterozygous mutations in *SIX3* and *SHH* are associated with schizencephaly and further expand the clinical spectrum of holoprosencephaly. *Hum Genet* **2010**, *127*, (5), 555–61.
2. Jacob, F. D.; Ramaswamy, V.; Andersen, J.; Bolduc, F. V., Atypical Rett syndrome with selective *FOXP1* deletion detected by comparative genomic hybridization: case report and review of literature. *Eur J Hum Genet* **2009**, *17*, (12), 1577–81.